BibTex RIS Cite

Efficiency of Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration

Year 2015, Volume: 40 Issue: 4, 757 - 765, 02.10.2015
https://doi.org/10.17826/cutf.99619

Abstract

Purpose: To evaluate the efficiency of the treatment of intravitreal ranibizumabin on the functions of lesion size and visual outcome in neovascular age-related macular degeneration cases. Material and Methods: Age-related macular degeneration diagnosis of 71eyes of 59 patients were analyzed retrospectively. Best-corrected visual acuity (BCVA), biomicroscopic examination, intra ocularpressure and fundus examinations were noted about the cases. In order to evaluate the effiency of IVR treatment, widest lesion diameter (WLD) of choroidal neovascularization (CNV) and BCVA were compared statistically, before and after treatment according to fundus fluorescein angiography (FFA). Results: The mean follow-upperiod was 14±5 months. Snellen BCVA was found 0.13±0.09 before treatment and was found 0.22±0.16 after treatment according to Snellen. A statistically significant increase was detected in BCVA after IVR teatment. WLD was calculated 4040±117μm before treatment and 3620±128μm after treatment. After IVR treatment a statistically significant decrease was founded in WLD. Conclusion: In our study, an increase in BCVA and a decrease in WLD were observed with the treatment of IVR in wet AMD cases. IVR was made out to be an effective and safe treatment. It can be thought that an obvious improvement was achieved acording to anatomic and visual acuity.

References

  • Spaide R. Etiology of late-age-related macular disease. In Alfaro DV. Age-related macular degeneration (A Comprehensive Textbook). Lippincott Williams&Wilkins; 2006;3:23-39.
  • Resnikoff S, Pascolini D,Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP et al. Global data on visual impairment in the year 2002. Bulletin of the WHO. 2004;82:844-51.
  • Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration; applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007;144:627-37.
  • Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol. 2012;6:1175- 86.
  • Börümcek EY. Yaşa Bağlı Maküla Dejeneresansında
  • Risk Faktörleri. XXVII. Ulusal Oftalmoloji Kursu; Retina “Güncel Tanı ve Tedavi”, 11–13 Nisan, Ankara. 2008;23-8.
  • World Health Organization. Main causes of visual impairment. World Health Organization. Geneva, Erişim:http://www.who.int/blindness/causes/en/index. html. Erişim tarihi: 12.04.2009.
  • Campa C, Harding SP. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets. 2011;12:173-81.
  • Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer Wet al.A variable-dosing regimen with intravitreal ranibizumab for neovascular age- relatedmacular degeneration:Year 2 of the PrONTO Study. Am. J. Ophthalmol. 2009;148:43-58.
  • Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO et al. Safety and efficacy of a flexible dosing regimen of ranibizumabin neovascular age-related macular degeneration: The SUSTAIN Study. Ophthalmology. 2011;118:663-71.
  • TurgutB, KasarK, CanNB, ÇelikerÜ.Yaşa Bağlı Maküla Dejeneresansında İntravitreal Ranibizumab Enjeksiyonu Sonuçlarımız. Ret-Vit. 2012;20:27-30.
  • Şengül A, Artunay Ö, Yüzbaşıoğlu E, Rasier R, Şenel A, Bahçecioğlu H. Yaşa Bağlı Maküla Dejenerasyonuna Neovaskülarizasyonlarında İntravitreal Ranibizumab Tedavi Sonuçlarımız. Ret-Vit. 2010;18:143-48.
  • Kılıç M, Yiğit U, Onur İU, Özkaya A, Keskin Ş. Yaş Tip Yaşa Bağlı Maküla Dejenerasyonu Olgularımızda İntravitreal Ranibizumab Enjeksiyonu Sonuçlarımız. Ret-Vit. 2012;20:129-33.
  • Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophtalmology. 2009;116:1740-7.
  • Ünlü N, Acar MA, Üney G, Hazırolan D, Altıparmak EU. Yaşa Bağlı Maküla Dejeneresansında Anti-VEGF Tedavisinde Rekürens Zamanı. Ret-Vit. 2012;20:22- 6.
  • Monés J, Biarnés M , Trindade F,Casaroli-Marano R. FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity. Graefes Arch Clin Exp Ophthalmol. 2012;250:1737-44.
  • Rotsos T, Patel PJ, Chen FK, Tufail A. Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration. Clin Ophtalmol. 2010;4:1271-5.
  • Moutray T, Alarbi M, Mahon G, Stevenson M, Chakravarthy U.Relationships between clinical measures of visual function, flourescein angiogrephic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation. Br J Ophthalmol 2008;92:361-4.
  • Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR; MARINA Study Group.Boyer DS, Antazsyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab for neovascular age-related macular degeneration. Ophthalmology 2007;114:246-52.
  • You JY, Chung H, Kim HC. Evaluation of changes in choroidal neovascularization secondary to age- related maculardegeneration after anti-VEGF therapy using spectral domain optical coherence tomography. Curr Eye Res. 2012;37:438-45.
  • Arias L, Roman I, Masuet-Aumatell C, Rubio MJ, Caminal JM, Catala J et al.One-yearresults of a flexibleregimen with ranibizumab therapy in macular degeneration: relationship with the number of injections.Retina 2011;31:1261-7.

Yaş Tip Yaşa Bağlı Makula Dejenerasyonunda İntravitreal Ranibizumab Enjeksiyonunun Etkinliği

Year 2015, Volume: 40 Issue: 4, 757 - 765, 02.10.2015
https://doi.org/10.17826/cutf.99619

Abstract

Amaç: Yaşa bağlı makula dejenerasyonlu olgularda intravitreal ranibizumab tedavisinin lezyon çapı ve görme fonksiyonları üzerine etkinliğini araştırmak. Materyal Metod: Yaşa bağlı makula dejenerasyonlu tanısı alan 59 hastanın 71 gözü geriye dönük olarak incelendi. Olgulara ait düzeltilmiş en iyi görme keskinlikleri, biyomikroskopik muayene, göz içi basınç ölçümü ve fundus muayene bulguları kaydedildi. İntravitreal ranibizumab tedavisinin etkinliğini değerlendirmek için tedavi öncesi ve sonrasında fundus floresein anjiyografi bulgularına göre koroid neovasküler membranın en geniş lezyon çapı ve düzeltilmiş en iyi görme keskinliği istatistiksel olarak karşılaştırıldı. Bulgular: Olgular ortalama 14±5 ay takip edildi. Tedavi öncesi ve sonrası düzeltilmiş en iyi görme keskinlikleri Snellen eşeline göre sırasıyla 0,13±0.09 ve 0,22±0,16 bulundu. İntravitreal ranibizumab sonrası düzeltilmiş en iyi görme keskinlikleri artışında istatistiksel olarak anlamlı fark saptandı. En geniş lezyon çapı tedavi öncesi ve sonrası sırasıyla 4040±117 μm ve 3620±128 μm bulundu. Tedavi sonrası lezyon çapında azalmanın istatistiksel olarak anlamlı olduğu görüldü. Sonuç: Çalışmamızda yaş tip yaşa bağlı makula dejenerasyonlu olgularda intravitreal ranibizumab tedavisi ile düzeltilmiş en iyi görme keskinliğinde artış ve lezyon çapında azalma sağlandığı gözlemlenmiştir. Anatomik ve görme keskinliği açısından net bir başarı sağlandığını düşünülmektedir.

References

  • Spaide R. Etiology of late-age-related macular disease. In Alfaro DV. Age-related macular degeneration (A Comprehensive Textbook). Lippincott Williams&Wilkins; 2006;3:23-39.
  • Resnikoff S, Pascolini D,Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP et al. Global data on visual impairment in the year 2002. Bulletin of the WHO. 2004;82:844-51.
  • Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration; applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007;144:627-37.
  • Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol. 2012;6:1175- 86.
  • Börümcek EY. Yaşa Bağlı Maküla Dejeneresansında
  • Risk Faktörleri. XXVII. Ulusal Oftalmoloji Kursu; Retina “Güncel Tanı ve Tedavi”, 11–13 Nisan, Ankara. 2008;23-8.
  • World Health Organization. Main causes of visual impairment. World Health Organization. Geneva, Erişim:http://www.who.int/blindness/causes/en/index. html. Erişim tarihi: 12.04.2009.
  • Campa C, Harding SP. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets. 2011;12:173-81.
  • Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer Wet al.A variable-dosing regimen with intravitreal ranibizumab for neovascular age- relatedmacular degeneration:Year 2 of the PrONTO Study. Am. J. Ophthalmol. 2009;148:43-58.
  • Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO et al. Safety and efficacy of a flexible dosing regimen of ranibizumabin neovascular age-related macular degeneration: The SUSTAIN Study. Ophthalmology. 2011;118:663-71.
  • TurgutB, KasarK, CanNB, ÇelikerÜ.Yaşa Bağlı Maküla Dejeneresansında İntravitreal Ranibizumab Enjeksiyonu Sonuçlarımız. Ret-Vit. 2012;20:27-30.
  • Şengül A, Artunay Ö, Yüzbaşıoğlu E, Rasier R, Şenel A, Bahçecioğlu H. Yaşa Bağlı Maküla Dejenerasyonuna Neovaskülarizasyonlarında İntravitreal Ranibizumab Tedavi Sonuçlarımız. Ret-Vit. 2010;18:143-48.
  • Kılıç M, Yiğit U, Onur İU, Özkaya A, Keskin Ş. Yaş Tip Yaşa Bağlı Maküla Dejenerasyonu Olgularımızda İntravitreal Ranibizumab Enjeksiyonu Sonuçlarımız. Ret-Vit. 2012;20:129-33.
  • Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophtalmology. 2009;116:1740-7.
  • Ünlü N, Acar MA, Üney G, Hazırolan D, Altıparmak EU. Yaşa Bağlı Maküla Dejeneresansında Anti-VEGF Tedavisinde Rekürens Zamanı. Ret-Vit. 2012;20:22- 6.
  • Monés J, Biarnés M , Trindade F,Casaroli-Marano R. FUSION regimen: ranibizumab in treatment-naïve patients with exudative age-related macular degeneration and relatively good baseline visual acuity. Graefes Arch Clin Exp Ophthalmol. 2012;250:1737-44.
  • Rotsos T, Patel PJ, Chen FK, Tufail A. Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration. Clin Ophtalmol. 2010;4:1271-5.
  • Moutray T, Alarbi M, Mahon G, Stevenson M, Chakravarthy U.Relationships between clinical measures of visual function, flourescein angiogrephic and optical coherence tomography features in patients with subfoveal choroidal neovascularisation. Br J Ophthalmol 2008;92:361-4.
  • Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR; MARINA Study Group.Boyer DS, Antazsyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab for neovascular age-related macular degeneration. Ophthalmology 2007;114:246-52.
  • You JY, Chung H, Kim HC. Evaluation of changes in choroidal neovascularization secondary to age- related maculardegeneration after anti-VEGF therapy using spectral domain optical coherence tomography. Curr Eye Res. 2012;37:438-45.
  • Arias L, Roman I, Masuet-Aumatell C, Rubio MJ, Caminal JM, Catala J et al.One-yearresults of a flexibleregimen with ranibizumab therapy in macular degeneration: relationship with the number of injections.Retina 2011;31:1261-7.
There are 21 citations in total.

Details

Primary Language English
Journal Section Research
Authors

Didem Şahin This is me

Ahmet Şahin

Adnan Aksoy This is me

Lokman Aslan This is me

Ali Şimşek This is me

Publication Date October 2, 2015
Published in Issue Year 2015 Volume: 40 Issue: 4

Cite

MLA Şahin, Didem et al. “Efficiency of Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration”. Cukurova Medical Journal, vol. 40, no. 4, 2015, pp. 757-65, doi:10.17826/cutf.99619.